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ABSTRACT: Bacterial biofilms, often impenetrable to antibiotic medications, are a leading
cause of poor wound healing. The prognosis is worse for wounds with biofilms of antimicrobial-
resistant (AMR) bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA),
methicillin-resistant S. epidermidis (MRSE), and multi-drug resistant Pseudomonas aeruginosa
(MDR-PA). Resistance hinders initial treatment of standard-of-care antibiotics. The persistence
of MRSA, MRSE, and/or MDR-PA often allows acute infections to become chronic wound
infections. The water-soluble hydrophilic properties of low-molecular-weight (600 Da) branched
polyethylenimine (600 Da BPEI) enable easy drug delivery to directly attack AMR and biofilms
in the wound environment as a topical agent for wound treatment. To mitigate toxicity issues, we have modified 600 Da BPEI with
polyethylene glycol (PEG) in a straightforward one-step reaction. The PEG−BPEI molecules disable β-lactam resistance in MRSA,
MRSE, and MDR-PA while also having the ability to dissolve established biofilms. PEG-BPEI accomplishes these tasks
independently, resulting in a multifunction potentiation agent. We envision wound treatment with antibiotics given topically, orally,
or intravenously in which external application of PEG−BPEIs disables biofilms and resistance mechanisms. In the absence of a
robust pipeline of new drugs, existing drugs and regimens must be re-evaluated as combination(s) with potentiators. The PEGylation
of 600 Da BPEI provides new opportunities to meet this goal with a single compound whose multifunction properties are retained
while lowering acute toxicity.
■ INTRODUCTION
To counter the rise of antibiotic resistant infections, existing
drugs and regimens are coupled with potentiators that
overcome antimicrobial resistance (AMR) or biofilms.1−3 In
contrast, multipurpose potentiators offer therapeutic advan-
tages by counteracting resistance and biofilms.1,3−8 Low-
molecular-weight (600 Da) branched polyethylenimine (600
Da BPEI) has the ability to overcome AMR in staphylococci
and Pseudomonas aeruginosa, potentiating penicillins, carbape-
nems, cephalosporins, and macrolides.4,9−14 Nevertheless, the
presence of primary amines creates toxicity issues that are
paramount. In vivo toxicity issues are mitigated by attaching a
low-molecular-weight polyethylene glycol (PEG) group to 600
Da BPEI (PEG-BPEI). The need to couple potentiators with a
standard-of-care antibiotic creates barriers to developing
therapy for systemic bacteremia where matching the
pharmacokinetic and pharmacodynamics of each component
is essential. Instead, the most promising therapeutic oppor-
tunities exist with treating bacterial infections of acute and
chronic wounds. As a topical agent for wound treatment, the
water-soluble properties of the bioactive moiety, 600 Da BPEI,
and the attached PEG group enable easy drug delivery to
directly attack AMR and biofilms in the wound environment.
The hydrophilic properties also mitigate problems with
binding to proteins. We have shown that 600 Da BPEI does
not suffer from detrimental protein binding using antibiotic
potentiation assays in the presence of fetal bovine serum.10
Additionally, 600 Da BPEI has low in vitro toxicity10 that
differentiates it from colistin10 and polymyxins.15 The
advantages of using 600 Da BPEI as the active moiety arise
from its hydrophilic nature that enables a potentiation
mechanism of action (MOA) involving binding to the outer
cellular envelope without disrupting the membrane bilayer.4
For chronic wound infections associated with AMR bacteria
and their biofilms, treatment options are scarce. Bacterial
biofilms, often impenetrable to antibiotic medications, are a
leading cause of poor wound healing.16 Patients afflicted with
these chronic wounds suffer from physical pain, disabilities,
psychological and emotional stresses, and poor quality of life.
Current in-patient treatments include cleansing, debridement,
maintaining a moist tissue environment, and, when possible,
eliminating the underlying pathology or factors that contribute
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to poor wound healing.17 In advanced cases, amputation may
become necessary. Death, especially in elderly patients, may
result from sepsis associated with chronic wounds. Survival is
determined by patient age, comorbidities, severity of the acute
infection, timely treatment, and effective treatment.18 While
the first two factors are beyond the control of pharmaceutical
therapy, antibiotics can be used effectively against susceptible
infections. For antibiotic-resistant infections, the best practices
for effective in-patient intervention are strict sanitary guidelines
and antibiotics, such as intravenous vancomycin plus
piperacillin/tazobactam or IV treatment with new antibiotics
of last resort.17 Nevertheless, biofilms and antimicrobial
resistance create substantial technological barriers to treating
chronic wound infections. This presents a significant and
critical need for new ways to counteract biofilms and
antimicrobial resistance simultaneously. In the absence of a
robust pipeline of new drugs, existing drugs and regimens must
be re-evaluated as combination(s) with potentiators. Ideally,
the potentiator should be a single compound with multi-
function and broad-spectrum properties that disable biofilms
and antibiotic resistance. We have discovered such a
compound. PEG-BPEI is a potentiator that disables β-lactam
resistance in MRSA, MRSE, and MDR-PA and disrupts their
biofilms. We envision wound treatment with antibiotics given
topically, orally, or intravenously in which external application
of PEG-BPEIs disables biofilms and resistance mechanisms.
■ RESULTS AND DISCUSSION
Even if a drug is effective, toxicity can preclude its clinical use.
According to Wiegand et al., high-molecular-weight BPEIs
(over 25,000 Da) are toxic; however, 600 Da BPEI has high
biocompatibility and a low likelihood for mutagenesis.19 This
report demonstrated BPEI’s safety, biocompatibility, and
antimicrobial properties, but it did not evaluate BPEI’s synergy
with antibiotics against MDR bacteria and their biofilms.19 We
believe it is possible to increase drug safety while retaining
potentiation by reacting the epoxy group of a polyethylene
glycol monoglycidyl epoxide with one of the amine groups on
600 Da BPEI in a straightforward one-step reaction under mild
conditions (Figure 1). PEGylation has a strong foundation in
medicinal chemistry,20−22 and data show that PEGylation of
cationic amine polymers reduces toxicity.23,24 The PEG-BPEIs
are not prodrugs, they are stable entities that balance cationic
properties for binding to anionic species (teichoic acids,
lipopolysaccharides, and biofilm extracellular polymeric sub-
stance) with hydrophilic properties to promote faster antibiotic
diffusion and uptake.
The synthesis of PEGylated BPEI involves a simple
bimolecular substitution (SN2) epoxide ring-opening reaction
of a monofunctionalized PEG epoxide (2, Figure 1). PEG
epoxides are available in different molecular weights. Here, we
used 350 MW PEG. The reaction mechanism generally
involves nucleophilic attack by a primary amine on BPEI (1,
Figure 1). Using a one-to-one stoichiometry, the product (3) is
generated and denoted (PEG350)1-(BPEI600)1.
Nuclear magnetic resonance (NMR) spectroscopy was used
to follow the PEGylation reaction. The 1H NMR spectrum of
600 Da BPEI (1, Figure 2A) is composed of signals between
2.5 and 3 ppm assigned to backbone CH2 groups, while the
broad signal at ∼1.65 ppm is assigned to backbone amine
protons. Interaction between BPEI and water leads to proton
exchange processes that cause exchange-averaged broadening
of NMR signals, and CDCl3 NMR solvents are known to have
small amounts of residual water.25 These observations are
consistent with previously reported data for BPEI.26 The
spectrum for mPEG-epoxide (2, Figure 2B) has a very strong
signal for backbone CH2 groups at 3.65 ppm, while the
terminal methoxy group gives a 1H signal at 3.3 ppm.
Characteristic epoxide signals are observed at 2.6, 2.8, and
3.2 ppm. These signals are absent in the spectrum of
(PEG350)1-(BPEI600)1 (3, Figure 2C), indicating that the
reaction is complete. A similar conclusion was reached with
mPEG-epoxide reacting with a cellulose substrate.27 PEG has
also been grafted onto BPEI using an amide-linking approach
with the samples analyzed as aqueous solutions using NMR
spectroscopy.28,29
PEGylation addresses the weakness that 600 Da BPEI may
not be clinically viable because of its toxicity. The ability of
some cationic species to permeate the membranes of
eukaryotic cells causes toxicity that hinders drug development.
Toxicity is mitigated by lowering the number of primary
amines, such as Spero Therapeutic Inc.’s SPR741, a cyclic
peptide with three primary amines.30 This paradigm has been
verified for PEG-BPEI. PEGylating 600 Da BPEI lowers single-
Figure 1. PEGylation reaction of 600 Da BPEI and PEG to produce
(PEG350)1-(BPEI600)1.
Figure 2. 1H NMR spectra of (A) 600 Da BPEI, (B) mPEG-epoxide,
and (C) (PEG350)1-(BPEI600)1 dissolved in CDCl3. In panel (C),
the signals for the epoxide group is absent, indicating that the reaction
is complete.
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dose acute toxicity. Toxicity data was collected by TransPharm
Preclinical Solutions Inc., a contract research lab. The acute
toxicity LD0, or maximum tolerable dose (MTD), was
evaluated over 3 days using female ICR mice with daily
subcutaneous dosing (Figure S1). For 600 Da BPEI, the MTD
is 25 mg/kg. Adding a single 350 MW PEG group to 600 Da
BPEI, (PEG-350)1(BPEI-600)1 increases its MTD to 75 mg/
kg. These data show that subcutaneous PEG-BPEI, for instance
applied to a wound with exposed tissue layers, has lower acute
toxicity and is safer to use than 600 Da BPEI. Additional safety
studies to evaluate off-target effects will be needed in the
future. The strategy of disabling resistance with cationic
potentiators and reducing toxicity by reducing the number of
primary amines has strong precedence. Spero Therapeutics,
Inc. has a drug based on a polymyxin B derivative that binds to
lipopolysaccharides (LPSs) and increases the potency of
rifampicin, clarithromycin, and azithromycin.30,31 Unmodified
polymyxin B has five primary amines, while the Spero
compound, SPR741, is a peptide with three primary amines.
Phase 1a and 1b clinical trials demonstrate its tolerability and
pharmacokinetic profile.32,33 SPR741 has been proven useful
against Gram-negative pathogens such Escherichia coli,
Klebsiella pneumoniae, and Acinetobacter baumannii. Our
approach has advantages because, as described below,
(PEG350)1-(BPEI600)1 is a multifunctional broad-spectrum
antibiotic potentiator that also disrupts biofilms. Second, our
potentiators are neither cationic peptides nor peptide mimetics
that can disable biofilms but lack in vivo activity due to rapid
proteolytic degradation and/or protein binding in wounds.34,35
The PEG-BPEI synthesis requires a single straightforward
reaction using low-cost starting materials.
Here, 600 Da BPEI restores susceptibility of MRSE12,13 and
MRSA9−11 to β-lactam antibiotics by inhibiting the PBP2a/4
functionality. Here, checkerboard assays were conducted to
examine the potentiation activity of (PEG350)1-(BPEI600)1
when combined with oxacillin against MRSE and MRSA
(Table 1 and Figure S2). The minimum inhibitory
concentrations (MICs) of (PEG350)1-(BPEI600)1 and
oxacillin for all three tested strains are tabulated in Table 1.
The (PEG350)1-(BPEI600)1 MICs for MRSE 35984, MRSA
MW2, and MRSA USA300 are each 64 μg/mL. The oxacillin
MICs are 64 μg/mL for MRSE 35984, 32 μg/mL for MRSA
MW2, and 32 μg/mL for MRSA USA300. According to
standard EUCAST guidelines,36 these values denote oxacillin
resistance, the breakpoint MIC for resistance is ≥4 μg/mL,
while values <2 μg/mL denote oxacillin susceptibility. The
checkerboard assay data show that growth inhibition is
possible with different combinations of 600 Da BPEI and
oxacillin or (PEG350)1-(BPEI600)1 and oxacillin (Figure S2).
Synergistic effects are indicated when the fractional inhibitory
concentration index (FICI) is ≤0.5,36 which was found for all
three strains tested. Non-PEGylated BPEI was slightly more
effective than PEGylated 600 Da BPEI at overcoming oxacillin
resistance. Achieving an oxacillin MIC of 2 μg/mL against
MRSE 35984 required 3.3 μM 600 Da BPEI versus 33.7 μM
(PEG-350)1-(BPEI-600)1, 13.33 μM 600 Da BPEI versus 16.8
μM (PEG-350)1-(BPEI-600)1 for MRSA USA300, and 26.67
μM 600 Da BPEI versus 33.7 μM (PEG-350)1-(BPEI-600)1 for
MRSA MW2. The ability to increase antibiotic efficacy can be
described by a fourfold minimum potentiating concentration
(MPC4).
37 The MPC4-OXA for 600 Da BPEI was 3.33 μM for
MRSE 35984, 6.67 μM for MRSA USA300, and 13.33 μM for
MRSA MW2. For (PEG-350)1-(BPEI-600)1, the MPC4-OXA
was 16.8, 4.2, and 8.4 μM for these three species, respectively.
The differences between PEGylated and non-PEGylated 600
Da BPEI are likely caused by reducing the number of primary
amines in 600 Da BPEI by PEGylation and/or steric effects of
the PEG group. The methicillin resistance gene mecA is
responsible for synthesis of PBP2a, a 78 kDa transmembrane
protein that can block all bindings to β-lactams, enabling
MRSA/MRSE to survive in the presence of these antibiotics.
Wall teichoic acid (WTA) is known to be PBP2a’s cofactor,
Table 1. Minimum Inhibitory Concentrations (MIC) and Fractional Inhibitory Concentration Indices (FICI) of 600-Da BPEI
and (PEG-350)1-(BPEI-600)1 as Potentiators of β-Lactam Activity against MRSA, MRSE, and P. aeruginosa
e
MIC μg/mL (μM)
strain 600 Da BPEI OXAa OXAa + 600 Da BPEI FICI outcome
MRSE 35984 8 (13.3) 32 8 + 2 (3.3) 0.5 synergy
MRSA USA300 32 (53.3) 32 4 + 8 (13.3) 0.38 synergy
MRSA MW2 >64 (>106.7) 32 2 + 16 (26.7) 0.19 synergy
MIC μg/mL (μM)
strain PEG-BPEIb OXAa OXAa + PEG-BPEIb FICI outcome
MRSE 35984 64 (67.4) 64 8 + 16 (16.7) 0.38 synergy
MRSA USA300 64 (67.4) 16 2 + 16 (16.8) 0.38 synergy
MRSA MW2 64 (67.4) 16 4 + 16 (16.7) 0.5 synergy
MIC μg/mL (μM)
strain 600 Da BPEI PIPc PIPc,d + 600 Da BPEI FICI outcome
PA 27583 16 (26.7) 4 0.25 + 4 (6.7) 0.31 synergy
PA OU1 16 (26.7) 64 4 + 2 (3.3) 0.31 synergy
MIC μg/mL (μM)
strain PEG-BPEIb PIPc PIPc,d + PEG-BPEIb FICI outcome
PA 27583 64 (67) 4 0.5 + 16 (16.8) 0.31 synergy
PA OU1 256 (268) 64 4 + 32 (33.6) 0.19 synergy
aOxacillin (OXA) susceptibility breakpoints are resistant at ≥4 μg/mL and susceptible at <4 μg/mL. bPEG-BPEI = (PEG-350)1-(BPEI-600)1.
cPiperacillin (PIP) susceptibility breakpoints are resistant at ≥32 μg/mL and susceptible at <16 μg/mL. dPiperacillin only, no tazobactam added.
eConcentrations are listed in units of μg/mL, and the corresponding μM values are in parentheses for comparison between 600 Da BPEI and PEG-
BPEI.
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which localizes PBP2a to where to function.38−40 As with 600
Da BPEI, (PEG-350)1-(BPEI-600)1 bears positive charges
from the amine groups at physiological pH, allowing it to
electrostatically bind the negatively charged phosphodiester
backbone of WTA. Therefore, (PEG-350)1-(BPEI-600)1 likely
inhibits proper localization of PBP2a/4, disabling this
resistance factor and restoring susceptibility of MRSA and
MRSE to β-lactams.
Potentiation of piperacillin against P. aeruginosa is also
affected when 350 MW PEG is attached to 600 Da BPEI. The
strain P. aeruginosa 27853 is piperacillin susceptible (MIC ≤16
μg/mL), and the MPC4-PIP is 6.67 μM for 600 Da BPEI and
16.8 μM for (PEG-350)1-(BPEI-600)1 (Table 1). Against the
P. aeruginosa clinical isolate OU1, which is multidrug resistant,4
the MPC4-PIP of 600 Da BPEI is 1.67 μM, while 3.33 μM
lowers the piperacillin MIC to 8 μg/mL, which indicates
antibiotic susceptibility (Figure S3).36 However, (PEG-350)1-
(BPEI-600)1 is less effective as the MPC4-PIP is 8.4 μM, and it
takes 16.8 μM PEG-BPEI to lower the piperacillin MIC to
levels considered antibiotic susceptible (Figure S3). The MOA
for β-lactam potentiation involves 600 Da BPEI binding to the
anionic LPS in the outer membrane of P. aeruginosa.4 The
phosphate and carboxylate groups of LPS are located on the
lipid A and core oligosaccharides, approximately 1−2 nm away
from the acyl chains.41−43 These anionic sites allow for the
chelation of metals that stabilize the LPS layer and provide
targets for 600 Da BPEI binding. Cationic polymyxin B and
colistin also bind to these sites, but their hydrophobic alkyl
tails penetrate the LPS acyl chain region to disrupt membrane
integrity and cause widespread catastrophic disruption. The
MIC for polymyxins is low, 1−3 μg/mL.44 In contrast, 600 Da
BPEI has weaker antimicrobial action (MIC >26 μM, 16 μg/
mL) because, without hydrophobic regions, it does not disrupt
the membrane.4 Instead, 600 Da BPEI increases the ability of
β-lactams to traverse the O-antigen and core oligosaccharides
of LPS and reach porin transporters. It is likely that (PEG-
350)1-(BPEI-600)1 shares this MOA. The higher MIC and
slightly weaker potentiation property suggest that interactions
between LPS and PEG-BPEI are reduced by PEGylation.
Isothermal titration calorimetry (ITC) directly measures the
enthalpy of molecular binding interactions. We used ITC to
confirm interactions between 600 Da BPEI and LPS.4 A recent
report describes SPR741’s MOA as LPS binding.45 Likewise,
we posit a LPS-binding MOA for PEG-BPEIs. The isotherm
obtained from a titration of (PEG-350)1-(BPEI-600)1 with P.
aeruginosa LPS (Sigma #L8643) is shown in Figure 3. The
negative ΔH values indicate exothermic binding. This is due to
electrostatic attractions between the cationic bioactive moiety,
600 BPEI, and the anionic lipid A, inner-core and outer-core
oligosaccharide chains that chelate Mg2+ ions.46 However,
when compared to the isotherm for 600 Da BPEI (Figure 3A),
PEG-BPEI has a less exothermic interaction with P. aeruginosa
LPS (Figure 3B). Likewise, the molar ratio of PEG-BPEI to
LPS is approximately lower than that observed with 600 Da
BPEI. These data demonstrate that (PEG-350)1-(BPEI-600)1
does bind with LPS but that PEGylation reduces binding
energetics and the ability of a single 600 Da BPEI molecule to
bind with multiple LPS molecules. This is not surprising as the
PEG group would form a large steric barrier to shield some
cationic amines from their anionic targets while allowing other
amines to bind with LPS. This weakening of LPS binding may
explain why PEGylation of 600 Da BPEI reduces antibiotic
potentiation (Figure 3C). More (PEG-350)1-(BPEI-600)1, 17
μM, than 600 Da BPEI (3.3 μM) is needed to potentiate
piperacillin against MDR-PA (Figure S3). This weakness is
mitigated by considering that (PEG-350)1-(BPEI-600)1 has
lower in vivo toxicity (MTD = 75 mg/kg) than 600 Da BPEI
(MTD = 25 mg/kg), and as discussed below, this does not
cause β-lactam ring hydrolysis but does possess superior anti-
biofilm properties. While studies are underway to further
elucidate the MOA for PEG-BPEI, it is possible that the PEG
group prevents the active moiety, 600 Da BPEI, from reaching
Figure 3. Isothermal titration calorimetry data demonstrate that P.
aeruginosa LPS binds with (A) 600 Da BPEI and (B) (PEG-350)1-
(BPEI-600)1. The differences in binding energetics and molar ratio
are attributed to steric hindrance from the 350 MW PEG group
attached to 600 Da BPEI. This effect would also explain why
PEGylation reduces piperacillin potentiation, a paradigm illustrated in
panel (C).
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the phosphates of lipid A at the acyl chain interface. This
scenario may also explain why PEGylation increases drug
safety, perhaps by preventing PEG-BPEI from disrupting
eukaryotic membranes.
The ability of PEGylation to increase safety and lower the
acute toxicity is strong benefits that outweigh any reduction in
potentiation efficacy. Because the most likely use of (PEG-
350)1-(BPEI-600)1 would be as a topical application to acute
and chronic wounds containing MRSA, MRSE, and/or MDR-
PA bacteria, higher drug concentrations can be directly applied
to the wound. As noted above, PEG-BPEI exposure to
subcutaneous tissue does not cause adverse toxicity.
Furthermore, the benefits of (PEG-350)1-(BPEI-600)1 extend
beyond disabling β-lactam resistance It is important to
consider that primary amino groups could disrupt the β-
lactam ring of the antibiotics. A colorimetric assay of β-lactam
hydrolysis was performed with nitrocefin, a chromogenic
cephalosporin whose β-lactam ring, which is susceptible to β-
lactamase, mediated hydrolysis.47 Once hydrolyzed, the
degraded nitrocefin compound rapidly changes color from
yellow to red. As shown in Figure S4, the unmodified 600 Da
BPEI causes slight hydrolysis at a molar ratio of 0.017:0.005
(3.4:1), whereas (PEG-350)1-(BPEI-600)1 has a similar effect
at a molar ratio of 0.168:0.005 (33.6:1). Thus, PEGylation of
BPEI leads to a 100× reduction in hydrolytic activity of the
constrained β-lactam ring of nitrocefin. Bacterial biofilms play a
vital role in the ability of AMR pathogens to withstand
antibiotic therapy. They deploy a protective layer of
extracellular polymeric substances (EPSs) composed of
polysaccharides, extracellular DNA, and proteins. These
biomacromolecules are cross-linked and encase bacteria. The
resulting matrix hinders the diffusion and accessibility of
antibiotics and host immune agents. Treating wound biofilms
often involves antibiotic therapy plus mechanical debridement
and irrigation with saline that may contain detergents. The
presence of MRSA, MRSE, and/or MDR-PA renders many
standard-of-care antibiotics useless. Bacterial cells that remain
after cleansing survive antibiotic therapy, quickly populate the
wound bed, and regenerate the biofilm matrix. An advantage of
600 Da BPEI is its ability to disrupt biofilms of staph-
ylococci12,13,48 and P. aeruginosa.4 PEGylated 600 Da BPEI
retains these anti-biofilm properties and is a superior anti-
biofilm agent compared to non-PEGylated 600 Da BPEI.
Data from a crystal violet biofilm assay are shown in Figure
4. MRSE 35984 produces strong and consistent biofilms.
Biofilms were stained with crystal violet and treated with
(PEG-350)1-(BPEI-600)1, 600 Da BPEI, water, and acetic acid.
The supernatant was carefully transferred into a new plate for
the OD550 measurement, which corresponds to the amount of
dissolved biofilm (Figure 4B). The biofilm is dissolved with
214 μM (128 μg/mL) 600 Da BPEI, consistent with a previous
report where 214 μM 600 Da BPEI dissolved twice as much
MRSE 35984 biofilm as 53 (32 μg/mL) and 106 μM (64 μg/
mL) 600 Da BPEI.13 Adding 350 MW PEG to 600 Da BPEI
improves its anti-biofilm properties. The MRSE 35984 biofilm
is completely dispersed by 67.4 μM (PEG-350)1-(BPEI-600)1,
a concentration that is 3.6 times lower than the 214 μM 600
Da BPEI required to give the same results. This highlights the
biofilm-disrupting potential of (PEG-350)1-(BPEI-600)1 and
that PEGylation improves disruption. The biofilm EPS of
staphylococci contains a large component of poly-N-acetyl
glucosamine (PNAG) and anionic extracellular teichoic acid
and eDNA.49−51 These components facilitate and stabilize
biofilm formation. The primary amines of (PEG-350)1-(BPEI-
600)1 bind with anionic EPS moieties to disrupt biofilm
integrity and stability. The hydrophilic nature of (PEG-350)1-
(BPEI-600)1 increases the ability of antibiotics to penetrate the
biofilm matrix while simultaneously causing the biofilm to
disperse. The staphylococci cells become vulnerable to β-
lactam antibiotics when additional (PEG-350)1-(BPEI-600)1
molecules bind to the planktonic cells and disable PBP2a/4
resistance mechanisms.
Importantly, biofilms can be eradicated without dissolving
the EPS. For methicillin-resistant S. epidermidis (MRSE), we
can overcome oxacillin resistance in planktonic cells where the
MIC drops from 32 to 4 μg/mL with 6.67 μM 600 Da BPEI12
and 33.37 μM (PEG-350)1-(BPEI-600)1. Eradication of MRSE
biofilms requires a higher amount of oxacillin, MBEC = 512
μg/mL, because of barriers imposed by the biofilm EPS.13
However, 600 Da BPEI can weaken the EPS to increase
oxacillin activity without dissolving the EPS. The oxacillin
MBEC drops to 16 μg/mL in the presence of 13 μM 600 Da
BPEI.13 However, this 13 μM 600 Da BPEI does not dissolve
the biofilm according to the crystal violet assay. Rather, 214
μM 600 Da BPEI are required to disperse the biofilm EPS into
the solution.13 In the MBEC assay using the Calgary biofilm
device, biofilms are grown on polystyrene prongs on the lid of
a 96-well plate. After biofilms are established on the prongs,
they are transferred to a 96-well plate for treatment before
transferring to a third plate of media only, where sonication is
used to dislodge the biofilms from the prongs. Biofilms that
remain attached to the prongs during the treatment phase are
weakened by the treatment solution. In this case, 13 μM 600
Figure 4. Biofilm disruption assays using crystal violet to stain the
biomass. Preformed MRSE 35984 biofilms stained with crystal violet
and washed prior to treatment with different concentrations of (PEG-
350)1-(BPEI-600)1 or 600 Da BPEI, in addition to treatment with of
water only and acetic acid. Photographs of the stained biomass
dissolved by the test agent were transferred into a new plate, and the
biomass remaining in the original plate is in panel (A). The
absorbance of the dissolved biomass at 550 nm was measured and is
reported in panel (B). Error bars denote standard deviation (n = 6).
An asterisk indicates a significant difference between the treatments
and the negative control of water (t-test, p-value <0.01).
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Da BPEI was able to weaken the MRSE biofilm, allowing 16
μg/mL oxacillin to kill the cells in the biofilm EPS that
remained attached to the prong.
■ CONCLUSIONS
PEGylated BPEI is a multifunction potentiator. It disrupts
biofilms that are otherwise impenetrable to antibiotics and
counteracts β-lactam resistance mechanisms. These events,
biofilm dispersal and β-lactam potentiation, occur through
independent mechanisms. Overcoming β-lactam resistance in
staphylococci involves binding with anionic cell wall teichoic
acids that prevent the function and localization of PBP4
enzymes.9−13,48 Potentiation against P. aeruginosa occurs when
the active moiety, 600 Da BPEI, binds to anionic LPS in the
cell envelope. This increases drug influx by facilitating access to
porin transporters without membrane disruption that occurs
with polymyxin B and colistin.4 Biofilm dispersal is possible
because the bioactive moiety, 600 Da BPEI, can bind to
anionic species in the EPS matrix. Compared to 600 Da BPEI,
(PEG-350)1-(BPEI-600)1 has superior biofilm dispersal
properties and lower acute toxicity, although the β-lactam
potentiation activity is slightly reduced. These data suggest that
(PEG-350)1-(BPEI-600)1 is likely to be more favorable for
therapeutic opportunities than 600 Da BPEI.
Skin or soft-tissue infections (SSTIs) arise from abrasions,
nonsurgical wounds, burns, or chronic health problems.52 For
example, diabetic foot ulcers are the most common cause of
nontraumatic lower leg amputation in the United States.
Despite efforts to prevent and treat foot ulcers, each year about
108,000 Americans with diabetes will lose part of their lower
extremities because a foot ulcer becomes infected and does not
heal.53 Diabetic wounds often become chronic because they
stall in a suboptimal inflammatory phase of healing that is
perpetuated by a microbial infection with biofilm-forming
pathogens, resulting in an accumulation of microorganisms
embedded in a polysaccharide matrix.54,55 Employing (PEG-
350)1-(BPEI-600)1 as a means to treat chronic wounds
afflicted with biofilms of AMR bacteria not only attacks the
underlying pathology, but topical use mitigates drawbacks of
matching its pharmacokinetics (PK) and pharmacodynamics
(PD) with those of antibiotics. There is a strong likelihood of
developing a topical agent for wound treatment because the
water-soluble hydrophilic properties of PEGylated BPEI
appear to be perfectly suited for wound treatment where
straightforward drug delivery directly attacks AMR and
biofilms in the wound environment. We also recognize that
it is important to evaluate the full safety profile of PEGylated
BPEI and its impact on wound healing. These studies are
underway. The conceptual origin of PEG-BPEIs as antibiotic
potentiators is based on recognizing that cationic properties
allow binding to anionic targets, such as WTA, LPS, and EPS.
Identifying anionic targets for BPEI derives from our work
describing the equilibrium binding behavior of Ca2+ and Mg2+
with WTA,56,57 and the WTA metal-binding model has been
independently verified.58 Previously, we found that 600 Da
BPEI had low in vitro cytotoxicity with an IC50 of 1090 and
690 μg/mL (1817 and 1150 μM, respectively) on human
HeLa cells and HEK293, respectively. Additionally, lactate
dehydrogenase (LDH) assays showed that 600 Da BPEI has a
low nephrotoxicity of 3.5% at 63 μg/mL (106 μM), much
lower than that of colistin, which was >20% nephrotoxicity at
the same concentration tested.10 However, the in vivo toxicity
of 600 Da BPEI was concerning (MTD = 25 mg/kg), and thus
PEGylation was pursued to improve drug safety (MTD = 75
mg/kg).
A strength of PEG-BPEI is addressing the unmet medical
need for new therapies to treat wound infection caused by
prominent antibiotic-resistant Gram-positive and Gram-neg-
ative pathogens with a compound whose PEGylation reduces
toxicity, reduces β-lactam hydrolysis activity, and improves
anti-biofilm properties. However, we also recognize that the
utility PEG-BPEI may be restricted to topical treatment.
However, this does not imply limited impact on patient health.
For example, each year, virulent MDR-PA contributes to 4−6
million chronic infections that arise from 100 million skin and
soft-tissue infections (SSTIs).16,52,59−61 Chronic wounds
exacerbated by P. aeruginosa infection often result in
amputation.62,63 This outcome can be avoided by addressing
(1) antimicrobial resistance (AMR) against standard-of-care
antibiotics and (2) biofilms that stifle host defense and
antimicrobial activity. PEG-BPEI provides this opportunity.
■ METHODS
Materials. In this study, methicillin-resistant S. epidermidis
35984, methicillin-resistant S. aureus USA300 (BAA-1717),
and P. aeruginosa 2785 bacteria were purchased from the
American Type Culture Collection. Additionally, MDR-PA
OU1 was obtained from clinical isolates from the University of
Oklahoma Health Sciences Center using appropriate IRB
protocols and procedures. MRSA MW2 (referenced in
Campbell et al., 201164) was a generous gift from Dr. Suzanne
Walker. Chemicals and antibiotics were purchased from Sigma-
Aldrich. Then, 600 Da BPEI was purchased from Polysciences,
Inc. Monofunctionalized PEG epoxide was obtained from
Nanocs, Inc.
Synthesis and Characterization of (PEG-350)1-(BPEI-
600)1. Approximately 200 mg of 600 Da BPEI was added to a
small glass vial and dried overnight under high vacuum. The
vial was reweighed to determine the final mass of the dry BPEI.
This value was used to determine the amount of mPEG-
epoxide (350 MW) required to react with 600 Da BPEI in a
one-to-one stoichiometric ratio. The 600 Da BPEI was
dissolved in 3 mL of 100% ethanol with stirring. Afterward,
a solution of mPEG-epoxide dissolved in 3 mL of 100%
ethanol was added dropwise. The mixture was stirred at 60 °C
for 24 h. Afterward, the mixture was cooled, and the solvent
was removed under high vacuum for 72 h. A 1-D 1H NMR
spectrum was collected by dissolving a portion of the dry
reaction product in CDCl3 followed by transfer to a 3 mm
NMR tube. All NMR experiments were performed using a 28-
shim Agilent VNMRS-300 MHz equipped with a triple-
resonance PFG probe. Pulse sequences for each experiment
were supplied by Agilent. Data acquisition and processing were
completed using VNMRJ 2.2C software on the Red Hat Linux
4.03 operating system. MestreNova software was used to
analyze the spectra.
Checkerboard Assays. Checkerboard assays followed the
methods of Lam et al.12 to determine the synergistic effect
between (PEG-350)1-(BPEI-600)1 and antibiotics against
drug-resistant strains growing in cation-adjusted Mueller−
Hinton broth (CAMHB). Bacterial growth used CAMHB
media augmented with various amounts in serial dilutions of
(PEG-350)1-(BPEI-600)1 and/or antibiotic (oxacillin or
piperacillin) inoculated with bacterial cells from an overnight
culture (5 × 105 CFU/mL). Cells were grown at 37 °C. The
change in OD600 (optical density at 600 nm) was measured
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and recorded after 24 h of treatment. Each checkerboard trial
was done in triplicate using sterile Greiner CellStar flat bottom
polystyrene plates, catalog #655180.
In Vivo Toxicity Studies. Experiments to determine the
acute toxicity of 600 Da BPEI and (PEG-350)1-(BPEI-600)1
were performed by a contract research organization (Trans-
Pharm Preclinical Solutions, Jackson, MI). Fully immunocom-
petent, uninfected, ICR mice (4−6 weeks old, 18−20 g each,
Envigo, Inc.) were treated once a day for 3 days via
subcutaneous injection with low concentrations of 600 Da
BPEI or (PEG-350)1-(BPEI-600)1 and closely monitored for
adverse reactions. Adverse events and mortality were tracked
through study day 4. Mice were administered 6.25, 12.5, 25,
50, 75, and 100 mg/kg of 600 Da BPEI or (PEG-350)1-(BPEI-
600)1 once daily on day 0, 1, and 2 in a volume of 0.2 mL via
subcutaneous (sc) injection, beginning with the lowest dose
concentration before dosing the next highest concentration.
Mice in each group were closely observed for 15 min following
dose administration for adverse events prior to dosing the next
highest dose concentration. Both 600 Da BPEI and (PEG-
350)1-(BPEI-600)1 are very soluble in water, which was
formulated in phosphate-buffered saline (PBS) at 20 mg/mL
solution and handled in a manner to minimize endotoxin and
bacterial contamination. The solutions were sterilized by filter
sterilization prior to the initial dose. The mice could tolerate
25 mg/kg 600 Da BPEI and 75 mg/kg (PEG-350)1-(BPEI-
600)1 with no visible toxicity. Mice injected with 50 mg/kg
600 Da BPEI and 100 mg/kg (PEG-350)1-(BPEI-600)1
succumbed to death within 5 min of treatment.
Biofilm Disrupting Assay. Overnight cultures of MRSE
35984 were used to inoculate a tissue culture treated in a 96-
well plate (100 μL of tryptic soy broth or TSB/well) with an
inoculation size of 1 μL/well (∼5 × 105 CFU/mL). The plate
was incubated at 35 °C for 48 h to allow the bacteria to form a
biofilm. It was then washed with water to remove planktonic
bacteria and stained with 100 μL of crystal violet solution
(0.1%) per well for 15 min. The stained plate was washed
excessively with water five times to remove any unbound stain
and air dried overnight. After washing to remove the crystal
violet, various concentrations of (PEG-350)1-(BPEI-600)1 or
600 Da BPEI were added to the stained-biofilm plate with a
total volume of 100 μL/well. Water only and 30% acetic acid
were also used for treatment. After 20 h, without touching the
biofilm layer in the bottom of the plate, a solubilized solution
containing dissolved, stained biomass in each treated well was
carefully transferred to a new 96-well plate for an OD550
measurement, which represents the corresponding amount of
biomass disrupted by each treatment.
Isothermal Titration Calorimetry (ITC). Isothermal
titration calorimetry (MicroCal PEAQ-ITC, Malvern Inc.,
Malvern, U.K.) was utilized to test the interactions between P.
aeruginosa-isolated LPS and PEGylated BPEI following the
methods of Lam et al.4 Briefly, solutions of (PEG-350)1(BPEI-
600) (1 mg/mL) and P. aeruginosa LPS (Sigma product
L8643, 5 mg/mL) prepared in 50 mM Tris−HCl (pH 7) were
titrated using injections of 2 μL lasting 4 s and separated by
150 s time intervals. Controls were performed, and the
experiment was done in duplicate.
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